



Special article

Scientific evidence of the duration of antibiotic treatment in intra-abdominal infections with surgical focus control[☆]



Estela Membrilla-Fernández,^{a,*} Silvia Gómez-Zorrilla,^b Ana María González-Castillo,^a Amalia Pelegrina-Manzano,^a Juan Guzmán-Ahumada,^a Nuria Prim,^c Daniel Echeverría-Esnal,^d Santiago Grau-Cerrato,^d Juan Pablo Horcajada-Gallego,^b Josep María Badía,^e Juan José Sancho-Insenser^a

^aServicio de Cirugía General y Aparato Digestivo, Hospital del Mar de Barcelona, Spain

^bServicio de Medicina Infecciosas, Hospital del Mar de Barcelona, Spain

^cServicio de Microbiología, Laboratorio de Referencia de Cataluña, Spain

^dServicio de Farmacia, Hospital del Mar de Barcelona, Spain

^eServicio de Cirugía General y Aparato Digestivo, Hospital de Granollers, Universitat Internacional de Catalunya, Spain

ARTICLE INFO

Article history:

Received 7 December 2021

Accepted 22 January 2022

Available online 24 June 2022

Keywords:

Antibiotic therapy

Antibiotic treatment

Intra-abdominal sepsis

Intra-abdominal infection

Antimicrobial treatment's length

Prophylactic antibiotics

Brief antibiotic prophylaxis and

abdominal surgery

Antimicrobial stewardship

A B S T R A C T

A non-systematic review of the published scientific evidence has been carried out on the duration of empirical antibiotic treatment in surgical intra-abdominal infections (IIA) with effective focus control. Given the progressive increase in antibiotic resistance, it is urgent to have strategies to reduce the pressure on the microbiota. The American guidelines made by Mazuski et al. of 2017¹, as the central axis in the recommendations of the duration of empirical antibiotic treatment in intra-abdominal infections with control of the focus and a bibliographic search of all the articles that contained the keywords in Pubmed and Google Scholar is added. 21 articles referring to the duration of empirical antibiotic treatment in intra-abdominal infection with control of the focus are collected. With the American guidelines and these articles, a proposal is prepared for the duration of empirical antibiotic treatment in patients without risk factors between 24 and 72 h. And in those who present risk factors, it should be individualized with active monitoring every 24 h of fever, paralytic ileus and leukocytosis (FIL), before an early detection of complications or the need for changes in antibiotic treatment. Short treatments are just as effective as those of longer durations and are associated with fewer adverse effects, therefore, daily adjusting and reassessing the duration of empirical antibiotic treatment is essential for better practice.

© 2022 The Author(s). Published by Elsevier España, S.L.U. on behalf of AEC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

[☆] Please cite this article as: Membrilla-Fernández E, Gómez-Zorrilla S, González-Castillo AM, Pelegrina-Manzano A, Guzmán-Ahumada J, Prim N, et al. Evidencia científica de la duración del tratamiento antibiótico en las infecciones intraabdominales con control de foco quirúrgico. Cir Esp. 2022;100:608-613.

* Corresponding author.

E-mail address: 94934@parcdesalutmar.cat (E. Membrilla-Fernández).

Evidencia científica de la duración del tratamiento antibiótico en las infecciones intraabdominales con control de foco quirúrgico

RESUMEN

Palabras clave:

Terapia antibiótica
Tratamiento antibiótico
Sepsis intraabdominal
Infección intraabdominal
Duración del tratamiento antimicrobiano
Antibióticos profilácticos
Profilaxis antibiótica breve y cirugía abdominal
Programas de optimización uso de antibióticos

El aumento progresivo de las resistencias antibióticas apremia el tener estrategias para disminuir la presión sobre la microbiota. La duración del tratamiento antibiótico empírico es variable, a pesar de las recomendaciones de las guías. Se ha realizado una revisión bibliográfica de la evidencia científica publicada sobre la duración del tratamiento antibiótico empírico en las infecciones intraabdominales (IIA) quirúrgicas con control de foco efectivo. Se analizan las guías americanas realizadas por Mazuski et al. de 2017¹, como eje central en las recomendaciones de la duración de tratamiento antibiótico empírico en infecciones intraabdominales con control del foco y se añade una búsqueda bibliográfica de todos los artículos que contuviesen las palabras claves en *Pubmed* y *Google Scholar*. Se recopilan 21 artículos referentes en la duración del tratamiento antibiótico empírico en la infección intraabdominal con control del foco. Con las guías americanas y estos artículos se ha elaborado una propuesta de duración del tratamiento antibiótico empírico en pacientes sin factores de riesgo entre 24 y 72 horas. Y en los que presentan factores de riesgo se habría de individualizar el mismo con monitorización activa cada 24 horas de fiebre, íleo paralítico y leucocitosis (FIL), ante una detección precoz de complicaciones o de necesidad de cambios en el espectro antibiótico. Los tratamientos cortos son igual de eficaces que los de duraciones más prolongadas y se asocian a menos tasa de efectos adversos, por tanto, ajustar y reevaluar diariamente la duración del tratamiento antibiótico empírico es fundamental para una mejor *praxis*.

© 2022 El Autor(s). Publicado por Elsevier España, S.L.U. en nombre de AEC. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Following a review of the published scientific evidence on the duration of empirical antibiotic treatment in surgical intra-abdominal infections with effective focus control commissioned by the 7 VINCat (Surveillance System of nosocomial infections in hospitals in Catalonia), it is recommended that this should be as limited as possible in patients without risk factors and evaluated individually in patients with risk factors. The reduction of the duration of empirical antibiotic treatment in this type of infection is based on scientific evidence that short courses of treatment are equally effective as longer courses and are associated with fewer adverse effects associated with the use of antibiotics. Thus, limiting the duration of antibiotic treatment is a useful strategy to reduce the deleterious effects of antimicrobials, both at the individual patient level (avoiding adverse effects derived from them) and at the collective level (avoiding the selection of resistant strains of bacteria, with the consequent reduction of antimicrobial resistance rates).

In this paper, a non-systematic review of the most relevant scientific articles related to the duration of antibiotic treatment in surgical intra-abdominal infections is carried out, reviewing the scientific evidence in this field.

Methodology

A review of the literature related to the duration of empirical antibiotic treatment in intra-abdominal infections with

surgical control of the focus was carried out in *Pubmed* and *Google Scholar* sources, both in Spanish and English: Antibiotic therapy, antibiotic treatment, intra-abdominal sepsis, intra-abdominal infection, intra-abdominal infection, antimicrobial treatment's length, prophylactic antibiotics, brief antibiotic prophylaxis and abdominal surgery, antimicrobial stewardship).

Definitions used

- 1 *Type of infection*: Surgically managed intra-abdominal infections were analysed, including: acute appendicitis, acute cholecystitis, acute diverticulitis, pancreatitis, mechanical bowel ischaemia and gastroduodenal perforation.
- 2 What is considered focus control? Complete, incomplete and no focus control
 - a) *Complete focus control*: a range of physical measures that eliminate the source of infection, limit contamination, block factors that facilitate persistent infection, and correct or control anatomical defects to restore physiological function. This is not limited to surgery, but includes other methods such as endoscopic or percutaneous. The following are considered as situations with control of the focus: exeresis of the affected organ, drainage or exteriorisation.
 - b) *No focus control*: no focus control manoeuvre has been necessary, e.g. acute diverticulitis with pericolic phlegmon with no or minimal systemic repercussions.
 - c) *Incomplete focus control*: due to technical difficulty or surgery that cannot completely isolate the source of infection. This will be the case for biliary fistulas,

duodenal stump dehiscences or oesophageal perforations.

Review result

In the guideline developed by Mazuski et al.¹ in 2017, on behalf of the American Surgical Infection Society, the following recommendations are set out:

- Do not administer empirical antibiotics for severe acute or necrotising pancreatitis or acute uncomplicated sigmoid diverticulitis.
- Uncomplicated acute sigmoid diverticulitis.
- Do not extend prophylaxis beyond 24 h in case of intra-abdominal contamination.
- In uncomplicated intra-abdominal infection, with control of the focus, a duration of antibiotic treatment of less than 24 h is recommended. Thus, in the case of acute appendicitis, cholecystitis without perforation or segmental small bowel ischaemia without perforation, 24 h of treatment is recommended.
- In complicated intra-abdominal infection with adequate control of the focus, antibiotic therapy duration of 3–5 days is recommended.
- In the case of complicated intra-abdominal infection without control of the focus, the duration is left to the surgeon's choice, based on the resolution of fever, paralytic ileus and leukocytosis (FIL). In these cases, they recommend at least 7 days if bacteraemia is present and no recommendation if septic shock is present.

In these same guidelines, the authors list a series of variables related to patient comorbidity, severity and evolution of the infection, and microbiology; and consider that patients with 2 or more of these risk factors should not be treated with 24-h empirical antibiotic treatment alone, even if the infection is uncomplicated. In these patients, they suggest that the duration of antibiotic treatment should be based on the resolution of the FIL.

In conjunction with this guideline, an exhaustive review of the scientific literature found 21 articles with recommendations and justifications for the duration of empirical antibiotic treatment in intra-abdominal infection. The following table specifies the articles found and analysed that address the duration of treatment (Table 1).

The review of the articles on this subject first offers us the DURAPOP study, published in 2018 by Montravers et al. in the journal *Intensive Care of Medicine*²¹. This is a prospective, multicentre, randomised study in which 21 French hospitals participated and which included Intensive Care Unit patients with intra-abdominal infection, in whom initial control of the focus had been achieved and who had received adequate empirical antibiotic coverage. A total of 249 patients were randomised to short-course (8 days) or long-course (15 days) regimens, with no differences in mortality or need for surgical reintervention between the two arms, so that short-course regimens (8 days) were considered to be

equally effective as longer courses (15 days) in critically ill patients.

Another literature review on the subject conducted in 2016 by Sartelli et al. and published in *Surgical Infections*²⁰, reviewed 29 articles and concluded that patients with effective control of the focus and who do not present criteria for FIL complication should receive between 3 and 5 days of antibiotic treatment. However, in critically ill patients with septic shock it is recommended to individualise treatment to the inflammatory response, which could be monitored analytically, in their case they proposed procalcitonin. He emphasised that antibiotic treatment in the case of uncomplicated intra-abdominal infection, if it was limited to an organ without peritoneal involvement and with effective control of the focus, antibiotic prophylaxis should be sufficient and postoperative antibiotic treatment would not be necessary^{11,18}.

In line with previous studies, a multicentre, randomised, open-label clinical trial (STOP-IT study), published in *The New England Journal of Medicine*¹⁹, enrolled 518 patients with complicated intra-abdominal infection with adequate focus control. Patients were randomised into 2 branches: short-course empirical antibiotic treatment (4 ± 1 day; 258 patients) or the control arm (260 patients), which consisted of receiving antibiotic treatment until 48 h after resolution of symptoms and signs of FIL with a maximum duration of 10 days, the mean duration of treatment in this arm being 8 days. In this study, no differences were observed in surgical site infection (6.6% vs. 8.8%; $p = .43$), recurrences (15.6% vs. 13.8%; $p = .67$), or 30-day mortality (1.2% vs. .8%; $p = .99$).

The idea of reduced post-operative antibiotic treatment has been discussed previously in studies focusing on a single origin of intra-abdominal infection, biliary and appendicular origin, by Regimbeau et al.¹⁸ and Mui et al.¹¹, respectively.

Regimbeau et al.¹⁸ published the results of a randomised, open-label, multicentre, postoperative, multicentre study of acute cholecystitis in 17 hospitals in France in the journal *JAMA* in 2014. The total number of patients included was 414 with acute calculous cholecystitis grade I and II, according to the 2007 *Tokyo Guidelines Classification*, out of an initial 479. Patients received 2 g of amoxicillin-clavulanic acid every 8 h before surgery and after surgery, one group did not continue with this treatment and another group received 5 days. There were no significant differences in surgical site infection after 30 days between the two groups. The postoperative infection rate was 17% (35 out of 207) in the no treatment group and 15% (31 out of 207) in the treatment group.

In the case of the study by Mui et al.¹¹, 269 patients undergoing open appendectomy for acute non-perforated appendicitis were randomised into 3 groups: the first group did not receive antibiotics after surgery, the second received 2 postoperative doses plus preoperative doses, and the third received 5 days of postoperative treatment. Antibiotic treatment was with cefuroxime and metronidazole in all branches. No significant differences were found between the 3 groups in terms of surgical site infection, although the group with the longest duration had lower infection rates than the other 2 (6.5%, 6.4% and 3.6%, $p = .64$). However, there were differences in antibiotic-related adverse effects, with significantly higher adverse effects in the group of patients receiving longer duration (0%, 1.1% and 4.8%; $p = .048$).

Table 1 – Bibliography by year of articles dealing with duration of empirical antibiotic treatment in intra-abdominal infection.

Year	Title	Journal	Author
1980	Leukocytosis at termination of antibiotic therapy: Its importance for intra-abdominal sepsis	Arch Surg	Lennard et al. ²
1981	Effect of prophylactic antibiotics in acute non-perforated appendicitis: a prospective, randomized, double-blind clinical study	Ann Surg	Busuttil et al. ³
1982	Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis	Ann Surg	Lennard et al. ⁴
1983	Acute non-perforating appendicitis. Efficacy of brief antibiotic prophylaxis	Arch Surg	Winslow et al. ⁵
1989	Antibiotic prophylaxis in acute non-perforated appendicitis. The Danish Multicenter Study Group III	Ann Surg	Bauer et al. ⁶
1994	Minimal antibiotic therapy after emergency abdominal surgery: A prospective study	BJS	Schein et al. ⁷
1995	Single-dose cefotetan or cefoxitin vs. multiple-dose cefoxitin as prophylaxis in patients undergoing appendectomy for acute non-perforated appendicitis	J Am Coll Surg	Liberman et al. ⁸
2000	Complicated appendicitis: Is there a minimum intravenous antibiotic requirement? A prospective randomised trial	Arch Surg	Taylor et al. ⁹
2004	The efficacy of postoperative oral antibiotics in appendicitis: A randomised prospective double-blinded study	Am Surg	Taylor et al. ¹⁰
2005	Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis	Anz J Surg	Mui et al. ¹¹
2005	Antibiotics vs. placebo for prevention of postoperative infection after appendectomy	Cochrane Database Syst Rev	Andersen et al. ¹²
2006	Can we define the ideal duration of atb therapy?	Surg Infect	Hedrick et al. ¹³
2008	A prospective, double blind, multicenter, randomized trial comparing ertapenem 3 vs. ≥5d in community-acquired IIA infection.	J Gastrointest Surg	Basoli et al. ¹⁴
2010	Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America	Surg Inf	Solomkin et al. ¹⁵
2014	Duration of antibiotic treatment after appendectomy for acute complicated appendicitis	Br J Surg	Van Rossem et al. ¹⁶
2014	Association of Excessive Duration of ATB Therapy for Intra-Abdominal Infection with Subsequent Extra-Abdominal Infection and Death: A Study of 2552 Consecutive Infections	Surg Infect	Riccio et al. ¹⁷
2014	Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis: A randomised clinical trial	JAMA	Regimbeau et al. ¹⁸
2015	Trial of short course antimicrobial therapy for intraabdominal infection	N Engl J Med	Sawyer et al. ¹⁹
2016	Duration of Antimicrobial Therapy in Treating Complicated Intra-Abdominal Infections: A Comprehensive Review	Surg Infect	Sartelli et al. ²⁰
2017	The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection	Surg Infect	Mazuski et al. ¹
2018	Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: The DURAPOP randomised clinical trial	Intensive Care Med	Montravers et al. ²¹

Even in previous reviews it had been questioned whether or not antibiotic prophylaxis was necessary in patients undergoing appendectomy. In a Cochrane systematic review conducted in 2003 by Andersen et al.¹² controlled clinical trials comparing the use of antibiotics vs. placebo in patients undergoing appendectomy for suspected acute appendicitis were evaluated and 45 studies with a total of 9576 patients were included in the review. The main conclusion of this study was that the use of antibiotic prophylaxis was associated with lower rates of postoperative infections, regardless of the type of appendicitis. Therefore, this study demonstrates the need for the use of antibiotic prophylaxis to prevent superficial and deep surgical site and organ space infection and should be routinely administered in these patients.

Going further back in time to 1994, Schein et al. published in the *British Journal of Surgery*²², a prospective study of 163 patients with any type of intra-abdominal infection. In this study, patients were stratified according to the type of intra-abdominal infection and antibiotic duration protocols were applied according to the degree of intra-abdominal infection, subsequently evaluating postoperative complications according to the protocol received. The aim of protocolising the duration of antibiotic treatment and differentiating between intra-abdominal contamination and established infection was to shorten the antibiotic regimens administered with the hypothesis that longer regimens did not improve patient outcomes and could even be counterproductive by favouring resistance, increasing the adverse effects of antibiotics and

Table 2 – Proposed duration of empirical antibiotic treatment in intra-abdominal infection with complete control of focus.

Proposed duration of empirical antibiotic treatment in patients without risk factors	
Pathology	Postoperative duration
Uncomplicated acute appendicitis	≤24 h
Acute perforated appendicitis	24–48 h
Apendicular peritonitis	72 h
Uncomplicated cholecystitis	≤24 h
Acute aggravogenous cholecystitis	24–48 h
Acute perforated acute cholecystitis	24–72 h
Acute non-fecaloid diverticulitis	48–72 h
Mechanical intestinal ischaemia	24–48 h
Gastroduodenal perforation <12 h	24–72 h

potentially favouring nosocomial extra-abdominal infections. Thus, the authors defined that patients with acute phlegmonous appendicitis, acute phlegmonous cholecystitis, uncomplicated diverticulitis, gastroduodenal perforations or traumatic bowel injuries of less than 12 h preoperatively or small bowel ischaemia without perforation would not receive empirical antibiotic treatment. Acute gangrenous appendicitis, acute gangrenous cholecystitis or acute cholecystitis with empyema without free pus would receive 24 h of empirical antibiotic treatment. The duration of antibiotic treatment would be 48 h in intra-abdominal infections with non-diffuse peritonitis and those traumatic intestinal injuries or gastro-duodenal perforations lasting more than 12 h. Finally, antibiotic therapy would be between 3 days and 5 days in cases of purulent peritonitis of any origin. With these guidelines, overall mortality was 2% and surgical wound infection 7%.

The concept of persistence of leukocytosis and fever in intra-abdominal sepsis as a guide in the maintenance of empirical antibiotic treatment was presented to the scientific community by Lennard et al.⁴ in 1982 in their publication in the journal *Annals of Surgery*. In their study, they compared the evolution of patients who underwent surgery based on the presence or absence of fever and leukocytosis after the end of antibiotic treatment. The study showed that patients with persistent leukocytosis or fever at the time of antibiotic discontinuation had an increased risk of postoperative intra-abdominal infection at 60 days postoperatively, by 33% if there was persistent leukocytosis and by up to 50% in those with persistent fever.

Discussion

The aim of this review is to highlight the fact that antibiotic treatment is complementary to other actions and that it must be assessed on a case-by-case and daily basis. Following this review and assessing the current situation of emergency surgery in intra-abdominal disease, with empirical antibiotic treatments with a broader spectrum and adapted to the patient's risk factors, with advances in diagnostic and monitoring mechanisms available both analytical and radiological, as well as, percutaneous interventional capacity and

Table 3 – Exceptions to the duration of this antibiotic treatment. Patients with >2 High-risk items.

Phenotypic/physiological risk factors
Older age >70 years
Malignancy
Significant cardiovascular involvement
Significant liver disease or cirrhosis
Significant renal disease
Hypoalbuminemia
Extensive infection or insufficient control of initial focus
Inability or delay in initial focus control
Diffuse/generalised peritonitis (4 intra-abdominal quadrants)
Elevated Mannheim index
Microbiological features with suspicion of resistant germs

Source: Mazuski et al.¹

the evidence of increasing antibiotic resistance, we propose a duration of antibiotic treatment according to the origin of the intra-abdominal infection similar to that proposed in Table 2, open to the decision of the surgeon responsible and individualising the duration in patients with risk factors for poor evolution (Table 3). In all cases, constant re-evaluation is required in all intra-abdominal infections every 24 h and if the duration of the intra-abdominal infection is longer than the time indicated, the presence of a possible intra-abdominal complication should be evaluated early.

The joint action of the interprofessional epidemiological surveillance teams in each centre is essential to guarantee the monitoring of resistance and the antibiotic pressure exerted by the empirical antibiotic regimens administered, both in terms of dose and duration. These teams are responsible for ensuring the optimisation of the antibiotic treatment used in the different departments and the continuous re-evaluation of these results.^{23–27}

Conflict of interests

The authors have no conflict of interests to declare.

REFERENCES

1. Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The surgical infection society revised guidelines on the management of intra-abdominal infection. *Surg Infect*. 2017;18(1).
2. Lennard ES. Leukocytosis at termination of antibiotic therapy. *Arch Surg*. 1980;115:918–21.
3. Busuttill RW, Davidson RK, Fine M, Tompkins RK. Effect of prophylactic antibiotics in acute nonperforated appendicitis. *Ann Surg*. 1981;194:502–9.
4. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. *Ann Surg*. 1982;195:19–24.
5. Winslow RE. Acute nonperforating appendicitis. *Arch Surg*. 1983;118:651–5.

6. Bauer T, Vennits BO, Holm B, Hahn-Pedersen J, Lysen D, Galatius H, et al. Antibiotic prophylaxis in acute nonperforated appendicitis. *Ann Surg.* 1989;209:307–11.
7. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. *Br J Surg.* 2005;81:989–91.
8. Liberman MA, Greason KL, Frame S, Ragland JJ. Single-dose cefotetan or cefoxitin versus multiple-dose cefoxitin as prophylaxis in patients undergoing appendectomy for acute nonperforated appendicitis. *J Am Coll Surg.* 1995;180:77–80.
9. Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: is there a minimum intravenous antibiotic requirement? A prospective randomized trial. *The Am Surg.* 2000;66:887–90.
10. Taylor E, Berjis A, Bosch T, Hoehne F, Ozaeta M. The efficacy of postoperative oral antibiotics in appendicitis: a randomized prospective double-blinded study. *Am Surg.* 2004;70:858–62.
11. Mui LM, Ng CSH, Wong SKH, Lam Y-H, Fung TMK, Fok K-L, et al. Optimum duration of prophylactic antibiotics in acute non-perforated appendicitis. *ANZ J Surg.* 2005;75:425–8.
12. Andersen B, Kallehave F, Andersen H. Antibiotics versus placebo for prevention of postoperative infection after appendectomy. *Cochrane Database Syst Rev.* 2003;CD001439.
13. Hedrick TL, Evans HL, Smith RL, Mcelearney ST, Schulman AS, Chong TW, et al. Can we define the ideal duration of antibiotic therapy? *Surg Infect.* 2006;7:419–32.
14. Basoli A, Chirletti P, Cirino E, D'Ovidio NG, Doglietto GB, Giglio D, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs ≥ 5 days in community-acquired intraabdominal infection. *J Gastrointest Surg.* 2008;12:592–600.
15. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Surg Infect.* 2010;11:79–109.
16. van Rossem CC, Schreinemacher MHF, Treskes K, van Hogezaand RM, van Geloven AAW. Duration of antibiotic treatment after appendectomy for acute complicated appendicitis. *Br J Surg.* 2014;101:715–9.
17. Riccio LM, Popovsky KA, Hranjec T, Politano AD, Rosenberger LH, Tura KC, et al. Association of excessive duration of antibiotic therapy for intra-abdominal infection with subsequent extra-abdominal infection and death: a study of 2,552 consecutive infections. *Surg Infect.* 2014;15:417–24.
18. Regimbeau JM, Fuks D, Pautrat K, Mauvais F, Haccart V, Msika S, et al. Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis. *JAMA.* 2014;312:145–54.
19. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med.* 2015;372:1996–2005.
20. Sartelli M, Catena F, Ansaloni L, Coccolini F, di Saverio S, Griffiths EA. Duration of antimicrobial therapy in treating complicated intra-abdominal infections: a comprehensive review. *Surg Infect.* 2016;17:9–12.
21. Montravers P, Tubach F, Lescot T, Veber B, Esposito-Farèse M, Seguin P, et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. *Intensive Care Med.* 2018;44:300–10.
22. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. *Br J Surg.* 1994;81:989–91.
23. Leeds IL, Fabrizio A, Cosgrove SE, Wick EC. Treating wisely. *Ann Surg.* 2017;265:871–3.
24. Charani E, Ahmad R, Rawson TM, Castro-Sanchez E, Tarrant C, Holmes AH. The differences in antibiotic decision-making between acute surgical and acute medical teams: an ethnographic study of culture and team dynamics. *Clin Infect Dis.* 2019;69:12–20.
25. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. *JAMA Surg.* 2019;154:590–8.
26. Riggi G, Abbo LM. *Infections in Surgery. Hot Topics in Acute Care Surgery and Trauma.* Cham: Springer; 2021. http://dx.doi.org/10.1007/978-3-030-62116-2_21.
27. Surat G, Vogel U, Wiegering A, Germer C-T, Lock JF. Defining the scope of antimicrobial stewardship interventions on the prescription quality of antibiotics for surgical intra-abdominal infections. *Antibiotics.* 2021;10:73.